Dianthus Therapeutics, Inc. (DNTH)
NASDAQ · Manufacturing · Pharmaceutical preparations
$88.55−$2.16 (−2.38%) on the dayAs of the close; data may be delayed.
DNTH price, last 12 months
Key stats
- Previous close
- $90.71
- Open
- $91.56
- Day range
- $88.34 – $92.89
- 52-week range
- $32.22 – $117.88
- Volume
- 522.7K
- Avg volume (20 days)
- 826.9K
- Market cap
- $5.0B
Performance
1W−8.5%
1M−20.1%
3M−7.1%
6M+7.4%
YTD+114.9%
1Y+138.1%
vs S&P 500, 1Y+121.3 pts
Technicals and fundamentals
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $5.0B